A Phase 1, Single-Center, Open-Label, Fixed-Sequence, 2-Period, 3-Part Study to Evaluate the One-Way Interaction of Calcium Carbonate, Omeprazole, or Rifampin on ACP-196 in Healthy Adult Subjects
Latest Information Update: 11 Jun 2021
At a glance
- Drugs Acalabrutinib (Primary) ; Calcium carbonate; Omeprazole; Rifampicin
- Indications B-cell lymphoma; B-cell prolymphocytic leukaemia; Bladder cancer; Chronic lymphocytic leukaemia; Diffuse large B cell lymphoma; Follicular lymphoma; Glioblastoma; Head and neck cancer; Infections; Mantle-cell lymphoma; Multiple myeloma; Non-Hodgkin's lymphoma; Non-small cell lung cancer; Ovarian cancer; Pancreatic cancer; Richter's syndrome; Waldenstrom's macroglobulinaemia
- Focus Pharmacokinetics
- Sponsors Acerta Pharma
- 11 Jun 2021 focus of the trial is on ACP-196. hence tagged it only as primary drug
- 11 Jun 2021 New trial record